These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1866552)

  • 61. Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections.
    Wiebe VJ; DeGregorio MW
    Rev Infect Dis; 1988; 10(6):1097-101. PubMed ID: 3060940
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Amphotericin B lipid complex in pediatric patients with invasive fungal infections.
    Walsh TJ; Seibel NL; Arndt C; Harris RE; Dinubile MJ; Reboli A; Hiemenz J; Chanock SJ
    Pediatr Infect Dis J; 1999 Aug; 18(8):702-8. PubMed ID: 10462340
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Treatment of peritonitis due to Curvularia and Trichosporon with amphotericin B.
    Ujhelyi MR; Raasch RH; van der Horst CM; Mattern WD
    Rev Infect Dis; 1990; 12(4):621-7. PubMed ID: 2385769
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Fungal urinary tract infections in the elderly: treatment guidelines.
    Jacobs LG
    Drugs Aging; 1996 Feb; 8(2):89-96. PubMed ID: 8845590
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
    De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
    Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The fluconazole era: management of hematogenously disseminated candidiasis in the nonneutropenic patient.
    Kramer KM; Skaar DJ; Ackerman BH
    Pharmacotherapy; 1997; 17(3):538-48. PubMed ID: 9165556
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
    Maharom P; Thamlikitkul V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK.
    Flynn TN; Kelsey SM; Hazel DL; Guest JF
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):543-50. PubMed ID: 10662479
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Advantages and drawbacks of amphotericin formulations in children: literature review].
    Bes DF; Sberna N; Rosanova MT
    Arch Argent Pediatr; 2012; 110(1):46-51. PubMed ID: 22307422
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections.
    Nivoix Y; Zamfir A; Lutun P; Kara F; Remy V; Lioure B; Rigolot JC; Entz-Werlé N; Letscher-Bru V; Waller J; Levêque D; Koffel JC; Beretz L; Herbrecht R
    J Infect; 2006 Jan; 52(1):67-74. PubMed ID: 16368463
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections.
    Drew R
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():36-44. PubMed ID: 16713192
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Guidelines for the treatment of generalized mycoses with amphotericin B].
    Rieth H
    Mykosen; 1967 Jan; 10(1):31-2. PubMed ID: 5589759
    [No Abstract]   [Full Text] [Related]  

  • 73. Incidence and management of proven and probable fungal infections in patients with acute leukemia: a single center experience.
    Fanci R; Casini C; Leoni F; Ciolli S; Bosi A
    J Chemother; 2004 Dec; 16(6):557-60. PubMed ID: 15700847
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Administration of amphotericin B].
    Borelli D
    Mycopathol Mycol Appl; 1972 Mar; 46(3):233-6. PubMed ID: 4622287
    [No Abstract]   [Full Text] [Related]  

  • 75. Amphotericin B serum concentrations during therapy.
    Fields BT; Bates JH; Abernathy RS
    Appl Microbiol; 1970 Jun; 19(6):955-9. PubMed ID: 5456013
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Implantation Mycoses and Invasive Fungal Infections with Cutaneous Involvement in Tropical Taiwan: An 11-Year Retrospective Study of a Medical Center.
    Hsu TJ; Lee CH
    J Fungi (Basel); 2023 Mar; 9(3):. PubMed ID: 36983490
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Observations on a yeastlike budding organism from human ulcers.
    Zapater RC; Lafuente I
    Sabouraudia; 1970 Feb; 7(4):247-8. PubMed ID: 5418303
    [No Abstract]   [Full Text] [Related]  

  • 78. Successful treatment of pulmonary aspergillosis due to
    Kashefi E; Seyedi SJ; Zomorodian K; Zare Shahrabadi Z; Zarrinfar H
    Clin Case Rep; 2021 May; 9(5):e04248. PubMed ID: 34084517
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lyophilized lecithin based oil-water microemulsions as a new and low toxic delivery system for amphotericin B.
    Moreno MA; Frutos P; Ballesteros MP
    Pharm Res; 2001 Mar; 18(3):344-51. PubMed ID: 11442275
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Large-scale multicentre study of fluconazole in the treatment of hospitalised patients with fungal infections. Multicentre European Study Group.
    Troke PF
    Eur J Clin Microbiol Infect Dis; 1997 Apr; 16(4):287-95. PubMed ID: 9177962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.